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In the last few decades, the chemistry of pyrrole and fused heterocyclic pyrrole de-
rivatives has received considerable attention owing to their synthetic and effective bio-
logical importance (1–3). Due to the presence of pyrrolo2,3-dpyrimidine moiety in some
important antibiotics (4, 5) and because of their structural resemblance to purines, interest
has arisen in the construction of such molecules. On the other hand, the thermal rear-
rangement of isomeric triazoles to their thermodynamically more stable isomers has
rarely been discussed in di- and triheterocycles (6–8).
The possibility of formation of isomeric triazolopyrimidines has been overlooked in
many reports (9–11). However, it was taken into consideration in the reaction of some
4-hydrazinopyrimidines with one carbon donor moiety, yielding the respective isomeric
triazolopyrimidines (6–8, 12–16). So far, isomeric conversion of pyrrolotriazolopyrimi-
dines was rarely reported (17). These findings encouraged us to undertake the synthesis
of some new pyrrolo2,3-dpyrimidine and fused pyrrolo2,3-dpyrimidine derivatives
hoping that they could be of promising chemical and biological interest.
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Pyrrole derivatives 1a,b were used as precursors for the
preparation of pyrrolo2,3-dpyrimidine derivatives 2a,b
–7a,b. Also, the formation and structure of different pyr-
rolotriazolopyrimidine derivatives 8a,b–11a,b were dis-
cussed. Some of the prepared products showed potent
antimicrobial activity.
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EXPERIMENTAL
All melting points were uncorrected and measured using an Electro-thermal IA
9100 apparatus (Shimadzu, Japan). Microanalytical data were performed by Vario, Ele-
mentar apparatus (Shimadzu). The IR spectra (KBr) were recorded on a Perkin-Elmer
1650 spectrophotometer (USA). 1H NMR spectra were determined on a Varian Mercury
(300 MHz) spectrometer (Varian, UK) in CDCl3 and the chemical shifts were expressed
in ppm relative to TMS as internal reference. Mass spectra were recorded on 70 eV EI
Ms-QP 1000 EX (Shimadzu).
Physicochemical and spectral data for the synthesised compounds are given in Tab-
les I and II.
Syntheses of compounds 1a, 2a and 3a were performed according to ref. 18.
Synthesis of 2-amino-1-(3,4-dichlorophenyl)-4-phenyl-1H-pyrrole-3-carbonitrile (1b)
To a solution of phenacyl bromide (2 g, 0.01 mol), 3,4-dichloroaniline (1.62 g, 0.01
mol) in ethanol (20 mL) and a saturated solution of sodium bicarbonate (5 mL) were added.
The reaction mixture was kept at 70 °C for 1 h, cooled, poured into cold water, filtered
off, dried. The obtained product was dissolved in an appropriate amount of ethanol (20
mL) and then malononitrile (0.66 g, 0.01 mol) was added portionwise, followed by so-
dium ethoxide (0.01 mol) and left to reflux till a solid was formed. Solvent was removed
under reduced pressure and the residue was recrystallized from methanol to give 1b.
Synthesis of 7-(3,4-dichlorophenyl)-3,7-dihydro-5-phenyl-7H-pyrrolo2,3-dpyrimidin-
-4-one (2b)
Compound 1b (0.01 mol) in formic acid (20 mL, 85%) was refluxed for 3 h, cooled,
poured onto ice-water to give a precipitate, which was filtered off, dried and recrystal-
lized from ethanol to afford 2b.
Synthesis of 4-chloro-7-(3,4-dichlorophenyl)-5-phenyl-7H-pyrrolo2,3-dpyrimidine (3b)
Compound 2b (0.01 mol) was refluxed in phosphorus oxychloride (30 mL) for 3 h,
cooled, poured onto ice-water to give a precipitate, which was filtered off, dried and re-
crystallized from ethanol to afford 3b.
Synthesis of (6,7-disubstituted-5-phenyl-7H-pyrrolo2,3-dpyrimidin-4-yl)-hydrazine
(4a,b)
Method A. – A mixture of 3a or 3b (0.01 mol) and hydrazine hydrate (5 mL, 98%)
was refluxed in absolute ethanol (20 mL) for 4 h. The solvent was removed under re-
duced pressure and the residue was recrystallized from methanol to give 4a and 4b.
Method B. – To a mixture of 5a or 5b (0.01 mol) in dry benzene (20 mL), hydrazine
hydrate (5 mL, 98%) was added under stirring at room temperature for 4 h. The solvent
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was removed under reduced pressure, and the residues were recrystallized from metha-
nol to give 4a and 4b. Compounds 4a and 4b prepared by this method are identical in all
respects (physical and spectral data) to those prepared by method A.
239
M. S. Mohamed et al.: Synthesis and antimicrobial screening of some fused heterocyclic pyrroles, Acta Pharm. 55 (2005) 237–249.










C H N Cl S

























































































































































































M. S. Mohamed et al.: Synthesis and antimicrobial screening of some fused heterocyclic pyrroles, Acta Pharm. 55 (2005) 237–249.
Table II. Spectral data of the newly prepared compounds






4.20 (brs, 2H, NH2, D2O exchangeable),







7.2–7.9 (m, 8H, Ar-H), 8.1 (s, 1H, C6-H),






1580 (C=N) 7.24–7.95 (m, 8H, Ar-H), 8.2 (s, 1H,
C6-H), 8.46 (s, 1H, C2-H)
4a 391 M+(100) 3430, 3330 (NH2)
3210 (NH)
4.9–5 (brs, 2H, NH2, D2O exchangeable),
5.3 (s, 2H, CH2), 6.9–7.4 (m, 16H, Ar-H,






4.8–4.9 (brs, 2H, NH2, D2O exchange-
able), 7.1–7.6 (m, 9H, Ar-H, NH, D2O
exchangeable), 7.8 (s, 1H, C6-H), 8.1 (s,
1H, C2-H)
5a 405 M+(90) 2210 (CN)
1560 (C=N)
1.30 (t, 3H, CH3), 2.40 (q, 2H, CH2), 5.10







1.32 (t, 3H, CH3), 2.50 (q, 2H, CH2),
6.8–7.6 (m, 9H, N=CH, Ar-H), 7.9 (s,
1H, C5-H)
6a 376 M+(100) 3430, 3330 (NH2) 4.9–5.0 (brs, 2H, NH2, D2O exchangeable),
5.35 (s, 2H, CH2), 6.8–7.3 (m, 15H,




3430, 3330 (NH2) 6.1–6.2 (brs, 2H, NH2, D2O exchange-
able), 7.4–7.9 (m, 8H, Ar-H), 8.2 (s, 1H,
C6-H), 8.4 (s, 1H, C2-H)
7a 390 M+(100) 3250 (NH) 2.6 (s, 3H, CH3), 5.3 (s, 2H, CH2),
6.8–7.5 (m, 16H, Ar-H, NH, D2O ex-




3265 (NH) 2.6 (s, 3H, CH3), 6.8–7.5 (m, 9H, Ar-H,
NH, D2O exchangeable), 7.8 (s, 1H,
C6-H), 8.2 (s, 1H, C2-H)
8a 401 M +(100) 3090, 2890 (CH)
1580 (C=N)
5.5 (s, 2H, CH2), 6.8–7.5 (m, 15H, Ar-H),






6.8–7.5 (m, 8H, Ar-H), 7.8 (s, 1H, C8-H),
8.2 (s, 1H, C2-H), 9.2 (s, 1H, C5-H)
9a 415 M+(100) 3060, 2870 (CH)
1520 (C=N)
1630 (C=C)
2.6 (s, 3H, C2-CH3), 5.5 (s, 2H, CH2),
6.9–7.5 (m, 15H, Ar-H), 9.05 (s, 1H, C5-H)
Synthesis of 2-ethoxymethylenamino-1,5-disubstituted-4-phenyl-1H-pyrrole-3-carboni-
trile (5a,b)
Compounds 1a or 1b (0.01 mol) were refluxed in triethyl orthoformate (20 mL) for
6 h. The solvent was removed under reduced pressure to give 5a or 5b.
Synthesis of 6,7-disubstituted-5-phenyl-7H-pyrrolo2,3-dpyrimidin-4-ylamine (6a,b)
Method A. – A mixture of 1a or 1b (0.01 mol) and formamide (30 mL) was heated at
110 °C for 3 h, cooled, poured onto ice-water to give precipitates, which were filtered off,
dried, and recrystallized from ethanol to afford 6a or 6b.
Method B. – To a solution of compound 5a or 5b (0.01 mol) in dry ethanol (20 mL),
ammonium hydroxide solution (5 mL, 25%) was added under stirring at 0 °C for 30 min,
then at room temperature for 4 h. The solvent was removed under reduced pressure and
the residue was recrystallized from methanol to give 6a or 6b. Compounds 6a and 6b
prepared by this method are identical in all respects (physical and spectral data) to those
prepared by method A.
Synthesis of (6,7-disubstituted-5-phenyl-7H-pyrrolo2,3-dpyrimidin-4-yl)-methyl-
amine (7a,b)
To a solution of 5a or 5b (0.01 mol) in dry ethanol (20 mL), methylamine solution (5
mL) was added under stirring at room temperature for 4 h. The solvent was removed
under reduced pressure and the residue was recrystallized from methanol to give 7a or
7b.
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Compd. No. Mass (m/z) IR (, cm–1) 1H NMR (, ppm)





2.7 (s, 3H, C2-CH3), 6.8–7.5 (m, 8H, Ar-H),
7.8 (s, 1H, C8-H), 9.3 (s, 1H, C5-H)
10a 477 M+(100) 1520 (C=N) 5.55 (s, 2H, CH2), 6.8–7.6 (m, 20H,
Ar-H), 9.2 (s, 1H, C5-H)
10b 459 M+4(11), 457
M+2(65), 455
M+(100)
1580 (C=N) 6.8–7.5 (m, 13H, Ar-H), 7.9 (s, 1H,
C8-H), 9.4 (s, 1H, C5-H)
11a 376 M+–NCS (100) 1580 (C=N) 3.9–4.2 (brs, 1H, SH, D2O exchangeable),
5.4 (s, 2H, CH2), 6.8–7.5 (m, 15H, Ar-H),
8.5 (s, 1H, C5-H)
11b 357 M+4–NCS (11)
355 M+2–NCS(65)
353 M+–NSC (100)
1580 (C=N) 4.1–4.3 (brs, 1H, SH, D2O exchangeable),
6.8–7.5 (m, 8 H, Ar-H), 7.9 (s, 1H, C8-H),




Method A. – A mixture of 4a or 4b (0.01 mol) and triethyl orthoformate (20 mL) was
refluxed for 6 h. The solvent was removed under reduced pressure and the residue was
recrystallized from methanol to give 8a or 8b.
Method B. – Compound 4a or 4b (0.01 mol) was refluxed in formic acid (20 mL, 85%)
for 5 h, cooled, and poured onto ice-water. The precipitate was filtered off, left to dry
and then recrystallized from ethanol to afford 8a or 8b. Compounds 8a and 8b prepared




Method A. – A mixture of 4a or 4b (0.01 mol) and triethyl orthoacetate (20 mL) was
refluxed for 8 h. The solvent was removed under reduced pressure and the residue was
recrystallized from methanol to give 9a or 9b.
Method B. – A mixture of 4a or 4b (0.01 mol), acetic anhydride (20 mL), and acetic
acid (10 mL) was refluxed for 5 h, cooled, and poured onto ice-water. The precipitate
was filtered off, left to dry and then recrystallized from ethanol to give 9a or 9b. Com-
pounds 9a and 9b prepared by this method are identical in all respects (physical and
spectral data) to those prepared by method A.
Synthesis of 7,8-disubstituted-2,9-diphenyl-7H-pyrrolo4,3-e1,2,4triazolo1,5-c-
pyrimidine (10a,b)
A mixture of 4a or 4b (0.01 mol), benzoyl chloride (5 mL) and trimethylamine (0.5
mL) was refluxed in dry ethanol (20 mL) for 6 h. The solvent was removed under re-
duced pressure and the residue was recrystallized from methanol to give 10a or 10b.
Synthesis of 7,8-disubstituted-2-mercapto-9-phenyl-7H-pyrrolo4,3-e1,2,4-
triazolo1,5-cpyrimidine (11a,b)
To an aqueous solution of 4a or 4b (0.01 mol) in ethanol (20 mL), carbon disulfide (10
mL) was added, then the reaction mixture was refluxed on a water-bath for 3 h, cooled,
poured onto ice-water, and neutralized with 2–3 drops of hydrochloric acid (35%). The
precipitate was filtered off, left to dry and recrystallized from methanol to give 11a or 11b.
Antimicrobial activity
The in vitro antimicrobial activity of the synthesized compounds was investigated
against several pathogenic representative Gram-positive bacteria (Staphylococcus aureus
ATCC 29231, Bacillus subtilis ATCC 10783, Mycobacterium phlei ATCC 1014, Streptococcus
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pyogenes ATCC 10782), Gram-negative bacteria (Escherichia coli ATCC 11105) and yeast
(Candida albicans ATCC 10231). All microorganisms used were obtained from the culture
collection of the Department of Microbiology and Immunology, Faculty of Pharmacy,
Helwan University, Cairo, Egypt. Compounds were tested against Escherichia coli and
Staphylococcus aureus in a nutrient broth, pH = 7.0, against Bacillus subtilis, Mycobacterium
phlei and Streptococcus pyogenes in the Bacto brain heart infusion broth, pH = 7.0, and
against Candida albicans in a broth containing 1% peptone, 2% dextrose, pH = 5.7. Esche-
richia coli of known antibiotic sensitivity served for control purposes.
Media for disc sensitivity tests were the nutrient agar and Muller-Hinton agar (MHA)
purchased from Difco (USA). Nonsterile powder of the tested compound was dissolved
in sterile DMSO to yield 2.0 µg mL–1, and passed through 0.2 µm membrane filter (Mil-
lipore Corp, USA). The filtrates were dispensed as 2 mL samples into sterile, small screw-
-capped vials, frosen and kept stored at –15 °C. The vials were refrozen after thawing.
Disc diffusion sensitivity test was done in the manner identical to that of Bauer et al.
(19). DMSO showed no inhibition zones. Amoxicilin (Bioanalyse, Turkey) and nystatin
(Sigma – Aldrich, USA) were used as reference substances.
RESULTS AND DISCUSSION
2-Amino-1H-pyrrole-3-carbonitrile derivatives 1a and 1b were used as key compo-
unds for this study and for syntheses of other fused heterocycles. Derivatives 1a-3a were
prepared as reported previously (18), while compound 1b was prepared by refluxing a
mixture of phenacyl bromide, 3,4-dichloroaniline, and malononitrile in dry ethanol. The
structure of compound 1b was confirmed by spectral data (Table II). The synthesis of
pyrrolo2,3-dpyrimidin-4-one derivative 2b was achieved by refluxing compound 1b
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Table III. Test of the synthesized compounds
Compoundsa



















Amoxicillinb 10 – – – – 13
Nystatinc – – – – 20 –
1b – – – – – 7
2a – 11 19 23 – 16
4b – – – – 13 11
6a – – 10 5 – 8
6b – – – – – 8
8a – – – – – 9
9a – – – – – –
a  = 2 µg mL–1 in DMSO
b  = 25 µg mL–1
c  = 4 µg mL–1
with formic acid. The IR spectrum of the latter compound showed the absence of cyano
group and the presence of CO and NH groups. Its 1H NMR spectrum in CDCl3 revealed
a signal at (, ppm): 12.20 (s, 1H, NH, exchangeable with D2O) (Table II). The latter com-
pound was converted to its corresponding 4-chloro derivative 3b by refluxing with phos-
phorus oxychloride; its MS gave the characteristic fragmentation pattern due to the presence
of three chlorine atoms (Table II).
Pyrrolo2,3-dpyrimidin-4-yl)-hydrazine derivatives 4a,b were obtained from deri-
vatives 3a,b by heating with hydrazine hydrate (Scheme 1). The 1H NMR spectra of
compounds 4a,b revealed signals characteristic of NH2 and NH, and their MS gave the
molecular ion peak as a base peak (Table II).
On the other hand, when the pyrrole derivatives 1a,b were refluxed with triethyl
orthoformate, they afforded the corresponding 2-ethoxymethyleneamino derivatives 5a,b
(Scheme 1). The spectral data of compounds 5a,b confirmed their structures (Table II).
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Many reports (17, 18, 20) stated that hydrazinolysis of compounds analogous to
5a,b, in polar solvents, gave the respective imino derivatives that could be isolated and
identified. However, our attempts to cyclize compounds 5a,b by stirring with hydrazine
hydrate in dry ethanol gave compounds 1a,b. Surprisingly, using a nonpolar solvent
(dry benzene), compounds 4a,b were obtained directly without isolation of the imino
derivatives. This could be explained by the formation of the imino derivatives first,
which in the presence of a base (excess hydrazine hydrate) underwent a Dimroth rear-
rangement to give the thermodynamically more stable derivatives 4a,b (8) (Scheme 2).
When compounds 1a,b were heated with formamide or compounds 5a,b were stir-
red with ammonium hydroxide solution they afforded pyrrolo2,3-dpyrimidin-4-ylamine
derivatives 6a,b, respectively. Also, when compounds 1a,b were stirred with methylamine
solution, they gave pyrrolo2,3-dpyrimidin-4-yl)-methylamine derivatives 7a,b, respec-
tively (Scheme 1). The IR and 1H NMR spectra of the aforementioned compounds re-
vealed the absence of the cyano group and the presence of NH2 in compounds 6a,b and
NH in compounds 7a,b (Table II).
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Previous observations revealed that 1,2,4triazolo4,3-cpyrimidines can isomerize
under different suitable reaction conditions to the thermodynamically more stable 1,2,4-
triazolo1,5-cpyrimidines (6, 8, 17). This isomerization was reported early by Miller et
al. (21, 22) when they treated 1,2,4triazolo4,3-cpyrimidine derivatives with an acid,
base, or thermally. In this investigation, and in continuation of our previous work (8, 23),
in the synthesis of different fused triazolopyrimidines, refluxing of compounds 4a,b
with formic acid or triethyl orthoformate (TEOF), acetic acid/acetic anhydride or triethyl
orthoacetate (TEOA), gave one and the same product assigned to the structures of 7,8-
-disubstituted-pyrrolo4,3-e1,2,4triazolo1,5-cpyrimidines 8a,b and 9a,b, respectively
(Scheme 3, Table II). Similarly, on refluxing compounds 4a,b with benzoyl chloride or
carbon disulfide, 7,8-disubstituted-2,9-diphenyl-7H-pyrrolo4,3-e1,2,4triazolo1,5-c py-
rimidines 10a,b or 7,8-disubstituted-2-mercapto-9-phenyl-7H-pyrrolo4,3-e1,2,4triazo-
lo1,5-cpyrimidine derivatives 11a,b were obtained, respectively (Scheme 3).
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In fact, the triazolo4,3-cpyrimidine derivatives could not be isolated even when
the reaction mixture was heated at a low temperature (40–60 °C) and for a short time.
TLC monitoring revealed the formation of more than one spot during the reaction, which
ended in formation of the final product. This could be explained by the formation of the
triazolo4,3-cpyrimidine derivatives first, which on heating (24) or in the presence of an
acid (8, 17, 21) or base (6, 8, 21) rearranged to the thermodynamically more stable form
of triazolo1,5-cpyrimidine derivatives through a series of ring opening and ring clo-
sure reactions (Scheme 2).
The antimicrobial activity of some newly synthesized compounds, 2-amino-1H-pyr-
role-3-carbonitrile, 1b, pyrrolo2,3-dpyrimidin-4-one derivative, 2a, pyrrolo2,3-dpyri-
midin-4-yl)-hydrazine derivative, 4b, pyrrolo2,3-dpyrimidin-4-ylamine derivatives 6a,
and 6b, 7,8-disubstituted-pyrrolo4,3-e1,2,4triazolo1,5-cpyrimidines 8a and 9a was
tested and the results are shown in Table III. It was noticed that compound 2a demon-
strated the highest inhibitory activity of all the tested compounds and the reference drug.
On the other hand, it was found that compounds 2a, 4b, and 6a revealed antibacterial
activity more effective than the reference drug. In general, it is obvious that compounds
of series a (substituted benzyl) were more effective than those of series b (substituted
dichlorophenyl). The promising antimicrobial activity of pyrrolo2,3-dpyrimidine deriv-
atives prompted us to add another heterocyclic ring (the triazole ring) hoping that it
would increase the activity, but unfortunately the activity decreased.
CONCLUSIONS
Evaluation of the new compounds established that pyrrolo2,3-dpyrimidin-4-one
derivative, 2a, showed improved antimicrobial activity compared to amoxicillin, while
the other compounds, pyrrolo2,3-dpyrimidin-4-yl)-hydrazine derivative, 4b, pyrrolo2,3
-dpyrimidin-4-ylamine derivatives 6a and 6b were weakly active against the tested mi-
croorganisms.
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S A @ E T A K
Sinteza i antimikrobno djelovanje fuzioniranih heterocikli~kih pirola
MOUSAD S. MOHAMED, AYMN E. RASHAD, MAGDY E. A. ZAKI i SAMAR S. FATAHALA
Pirolni derivati 1a,b uporabljeni su kao prekursori za pripravu derivata pirolo2,3 -
-dpirimidina 2a,b–7a,b. Raspravljano je i nastajanje struktura razli~itih derivata pirolo-
triazolopirimidina 8a,b–11a,b. Neki od sintetiziranih spojeva posjeduju izra`eno anti-
mikrobno djelovanje.
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